SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Docherty Neil G.)
 

Sökning: WFRF:(Docherty Neil G.) > Obesity is common i...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003837naa a2200553 4500
001oai:gup.ub.gu.se/297788
003SwePub
008240528s2020 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/2977882 URI
0247 a https://doi.org/10.1111/cob.124022 DOI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Martin, W. P.4 aut
2451 0a Obesity is common in chronic kidney disease and associates with greater antihypertensive usage and proteinuria: evidence from a cross-sectional study in atertiary nephrology centre
264 c 2020-08-26
264 1b Wiley,c 2020
520 a Obesity is a treatable risk factor for chronic kidney disease progression. We audited the reporting of body-mass index in nephrology outpatient clinics to establish the characteristics of individuals with obesity in nephrology practice. Body-mass index, clinical information and biochemical measures were recorded for patients attending clinics between 3(rd)August, 2018 and 18(th)January, 2019. Inferential statistics and Pearson correlations were used to investigate relationships between body-mass index, type 2 diabetes, hypertension and proteinuria. Mean +/- SD BMI was 28.6 +/- 5.8 kg/m(2)(n = 374). Overweight and obesity class 1 were more common in males (P= .02). Amongst n = 123 individuals with obesity and chronic kidney disease, mean +/- SD age, n (%) female and median[IQR] eGFR were 64.1 +/- 14.2 years, 52 (42.3%) and 29.0[20.5] mL/min/BSA, respectively. A positive correlation between increasing body-mass index and proteinuria was observed in such patients (r= 0.21,P= .03), which was stronger in males and those with CKD stages 4 and 5. Mean body-mass index was 2.3 kg/m(2)higher in those treated with 4-5 versus 0-1 antihypertensives (P= .03). Amongst n = 59 patients with obesity, chronic kidney disease and type 2 diabetes, 2 (3.5%) and 0 (0%) were prescribed a GLP-1 receptor analogue and SGLT2-inhibitor, respectively. Our data provides a strong rationale not only for measuring body-mass index but also for acting on the information in nephrology practice, although prospective studies are required to guide treatment decisions in people with obesity and chronic kidney disease.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
653 a chronic kidney disease
653 a diabetes mellitus
653 a diabetic kidney disease
653 a obesity
653 a overweight
653 a bariatric surgery
653 a sglt2 inhibitors
653 a outcomes
653 a glomerulopathy
653 a liraglutide
653 a mortality
653 a trials
653 a Endocrinology & Metabolism
7001 a Bauer, J.4 aut
7001 a Coleman, J.4 aut
7001 a Dellatorre-Teixeira, L.4 aut
7001 a Reeve, J. L. V.4 aut
7001 a Twomey, P. J.4 aut
7001 a Docherty, Neil G.u Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xdocme
7001 a O'Riordan, A.4 aut
7001 a Watson, A. J.4 aut
7001 a le Roux, Carel Wu Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences4 aut0 (Swepub:gu)xleroc
7102 a Göteborgs universitetb Institutionen för kliniska vetenskaper4 org
7730 t Clinical Obesityd : Wileyg 10:6q 10:6x 1758-8103x 1758-8111
8564 u https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/cob.12402
8564 8u https://gup.ub.gu.se/publication/297788
8564 8u https://doi.org/10.1111/cob.12402

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy